Changing therapy in HIV.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Changing therapy in HIV.

AIDS. 1996 Nov;10 Suppl 1:S27-30. Unique Identifier : AIDSLINE MED/97125601
Lange JM; NATEC, Academic Medical Centre, University of Amsterdam, The; Netherlands.

Abstract: AIM: To review recent developments in research into HIV and antiretroviral therapy and how these developments have affected the monitoring and treatment of HIV infection. DEVELOPMENTS AND THEIR IMPLICATIONS: More antiretroviral agents of different types have become available over recent years; combination therapy with these agents is proving to be more effective than monotherapy with zidovudine. Viral load is now known to be a better predictor of clinical outcome than CD4+ cell counts, and, now that it can be measured reliably in plasma or serum, clinicians can make better-informed decisions about initiation and alteration of therapy. It has become possible (though only on a small scale) to determine genotypic and phenotypic sensitivity of patients' viral isolates so that assessments of drug resistance can be made and drug choices tailored accordingly. As more becomes known about beneficial and potentially harmful interactions between antiretroviral drugs and about cross-resistance, maximally effective combination therapy regimens that do not limit subsequent options can be chosen. CONCLUSIONS: These developments mean that combinations of antiretrovirals can be selected to provide effective (> 2 logs) and prolonged suppression of viral load. Effective combination therapies that do not limit further treatment options, initiated at the appropriate time, should increase the extent and duration of antiretroviral activity and hence clinical benefit to patients.

Keywords: *Anti-HIV Agents/THERAPEUTIC USE *HIV Infections/DRUG THERAPY
970630
M9761250

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .